Parkinson's disease
Conditions
Brief summary
FDG-PET network analysis at baseline, 9 and 21 months
Detailed description
MDS-UPDRS part 3 in OFF-medication state and accelerometer-based parameters of physical activity, MDS-UPDRS part 3 in ON-medication state, MDS-UPDRS parts 1, 2 and 4, biofluid-based parameters at baseline, 9, 18 and 21 months, LEDD at baseline, 3, 6, 9, 12, 15, 18 and 21 months, PDQ-39, NMSQuest, ESS at baseline, 6, 12, 18 months, MoCA at baseline, 9 and 21 months, B-SIT at baseline, 9 and 18 months, MADRS at screening, 6, 12 and 18 months
Interventions
DRUGBydureon 2 mg powder and solvent for prolonged-release suspension for injection
DRUGPowder and solvent for prolongedrelease suspension for injection in pre-filled pen
Sponsors
Region Stockholm – SLSO
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FDG-PET network analysis at baseline, 9 and 21 months | — |
Secondary
| Measure | Time frame |
|---|---|
| MDS-UPDRS part 3 in OFF-medication state and accelerometer-based parameters of physical activity, MDS-UPDRS part 3 in ON-medication state, MDS-UPDRS parts 1, 2 and 4, biofluid-based parameters at baseline, 9, 18 and 21 months, LEDD at baseline, 3, 6, 9, 12, 15, 18 and 21 months, PDQ-39, NMSQuest, ESS at baseline, 6, 12, 18 months, MoCA at baseline, 9 and 21 months, B-SIT at baseline, 9 and 18 months, MADRS at screening, 6, 12 and 18 months | — |
Countries
Sweden
Outcome results
None listed